|Title||Neuronal Expression of UBQLN2 Exacerbates TDP-43 Pathology in TDP-43 Mice through Interaction with Ubiquitin.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Auteurs||Picher-Martel, V, Renaud, L, Bareil, C, Julien, J-P|
|Date Published||2018 Oct 30|
Mutations in the gene encoding ubiquilin-2 (UBQLN2) are linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). UBQLN2 plays a central role in ubiquitin proteasome system (UPS) and UBQLN2 up-regulation exacerbates TDP-43 cytoplasmic aggregates. To analyze interaction between UBQLN2 and TDP-43 and to produce a relevant ALS animal model, we have generated a new transgenic mouse expressing UBQLN2 under the neurofilament heavy (NFH) gene promoter. The UBQLN2 mice were then bred with our previously described TDP-43 mice to generate double-transgenic UBQLN2; TDP-43 mice. With low-expression levels of UBQLN2, the double-transgenic mice developed TDP-43 cytosolic accumulations in motor neurons starting at 5 months of age. These double-transgenic mice exhibited motor neuron loss, muscle atrophy, as well as motor and cognitive deficits during aging. The microglia from double-transgenic mice were hyperresponsive to intraperitoneal injection of lipopolysaccharide (LPS). In vivo and in vitro analyses suggested that extra UBQLN2 proteins can exacerbate cytoplasmic TDP-43 accumulations by competing with the UPS for binding to ubiquitin. Thus, increasing the pool of ubiquitin promoted the UPS function with ensuing reduction of TDP-43 cytosolic accumulations. In conclusion, the double-transgenic UBQLN2; TDP-43 mice provides a unique mouse model of ALS/FTD with enhanced TDP-43 pathology that can be exploited for drug testing.
|Alternate Journal||Mol. Neurobiol.|
|Grant List||143275 / / Canadian Insitutes of health research /|